A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia

Leuk Res. 2018 Sep:72:7-11. doi: 10.1016/j.leukres.2018.07.017. Epub 2018 Jul 21.

Authors

Maël Heiblig¹, Mohamed Elhamri¹, Xavier Thomas², Adriana Plesa³, Emmanuel Raffoux⁴, Sandrine Hayette⁵

Affiliations

¹ Hematology, Lyon-Sud Hospital, Pierre Bénite, France.
² Hematology, Lyon-Sud Hospital, Pierre Bénite, France. Electronic address: Xavier.thomas@chu-lyon.fr.
³ Laboratory of Cytology/Flow Cytometry, Lyon-Sud Hospital, Pierre Bénite, France.
⁴ Hematology, Saint-Louis Hospital, Paris, France.
⁵ Laboratory of Molecular Biology, Lyon-Sud Hospital, Pierre-Bénite, France.

PMID: 30059824
DOI: 10.1016/j.leukres.2018.07.017

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Adolescent
Adult
Aged
Benzylamines
Cyclams
Female
Heterocyclic Compounds / administration & dosage*
Heterocyclic Compounds / adverse effects
Humans
Leukemia, Myeloid, Acute / blood
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Recurrence

Substances

Benzylamines
Cyclams
Heterocyclic Compounds
plerixafor